Keywords: Pharma R&D, Productivity, Costs, Terminations, Deloitte, Thomson Reuters, OHE

Pharma R&D internal rate of return falls for a second year but shows signs of stabilizing

Article | 04 December 2012

The R&D internal rate of return (IRR) of leading pharmaceutical companies has fallen for a second successive year ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in